IDH1 and central nervous system cancer: IDH1R132H, the IDH1/2 mutation with relatively low D-2HG production capacity, is the most common mutation in gliomas; other mutations such as IDH1R132C have tenfold lower KM and have higher enzymatic efficiency [5, 40].